Biosimilar therapeutic peptides are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease.
The “Biosimilar Therapeutic Peptides Industry Forecast” looks at past sales and reviews total world Biosimilar Therapeutic Peptides sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar Therapeutic Peptides sales for 2023 through 2029. With Biosimilar Therapeutic Peptides sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Therapeutic Peptides industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar Therapeutic Peptides landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Therapeutic Peptides portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Therapeutic Peptides market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Therapeutic Peptides and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Therapeutic Peptides.
The global Biosimilar Therapeutic Peptides market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Biosimilar Therapeutic Peptides is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Biosimilar Therapeutic Peptides is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Biosimilar Therapeutic Peptides is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Biosimilar Therapeutic Peptides players cover Pfizer, GlaxoSmithKline, li Lilly and Company, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Amgen, AstraZeneca and Novartis AG, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Therapeutic Peptides market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Innovative
Generic
Segmentation by application
Cancer
Cardiovascular
Central Nervous Systems
Metabolic Disorders
Gastrointestinal Disorders
Dermatology
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GlaxoSmithKline
li Lilly and Company
Sanofi
Takeda Pharmaceuticals
Teva Pharmaceuticals
Amgen
AstraZeneca
Novartis AG
Novo Nordisk
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biosimilar Therapeutic Peptides Market Size 2018-2029
2.1.2 Biosimilar Therapeutic Peptides Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Biosimilar Therapeutic Peptides Segment by Type
2.2.1 Innovative
2.2.2 Generic
2.3 Biosimilar Therapeutic Peptides Market Size by Type
2.3.1 Biosimilar Therapeutic Peptides Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Biosimilar Therapeutic Peptides Market Size Market Share by Type (2018-2023)
2.4 Biosimilar Therapeutic Peptides Segment by Application
2.4.1 Cancer
2.4.2 Cardiovascular
2.4.3 Central Nervous Systems
2.4.4 Metabolic Disorders
2.4.5 Gastrointestinal Disorders
2.4.6 Dermatology
2.4.7 Others
2.5 Biosimilar Therapeutic Peptides Market Size by Application
2.5.1 Biosimilar Therapeutic Peptides Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Biosimilar Therapeutic Peptides Market Size Market Share by Application (2018-2023)
3 Biosimilar Therapeutic Peptides Market Size by Player
3.1 Biosimilar Therapeutic Peptides Market Size Market Share by Players
3.1.1 Global Biosimilar Therapeutic Peptides Revenue by Players (2018-2023)
3.1.2 Global Biosimilar Therapeutic Peptides Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilar Therapeutic Peptides Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biosimilar Therapeutic Peptides by Regions
4.1 Biosimilar Therapeutic Peptides Market Size by Regions (2018-2023)
4.2 Americas Biosimilar Therapeutic Peptides Market Size Growth (2018-2023)
4.3 APAC Biosimilar Therapeutic Peptides Market Size Growth (2018-2023)
4.4 Europe Biosimilar Therapeutic Peptides Market Size Growth (2018-2023)
4.5 Middle East & Africa Biosimilar Therapeutic Peptides Market Size Growth (2018-2023)
5 Americas
5.1 Americas Biosimilar Therapeutic Peptides Market Size by Country (2018-2023)
5.2 Americas Biosimilar Therapeutic Peptides Market Size by Type (2018-2023)
5.3 Americas Biosimilar Therapeutic Peptides Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar Therapeutic Peptides Market Size by Region (2018-2023)
6.2 APAC Biosimilar Therapeutic Peptides Market Size by Type (2018-2023)
6.3 APAC Biosimilar Therapeutic Peptides Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biosimilar Therapeutic Peptides by Country (2018-2023)
7.2 Europe Biosimilar Therapeutic Peptides Market Size by Type (2018-2023)
7.3 Europe Biosimilar Therapeutic Peptides Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biosimilar Therapeutic Peptides by Region (2018-2023)
8.2 Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Type (2018-2023)
8.3 Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Biosimilar Therapeutic Peptides Market Forecast
10.1 Global Biosimilar Therapeutic Peptides Forecast by Regions (2024-2029)
10.1.1 Global Biosimilar Therapeutic Peptides Forecast by Regions (2024-2029)
10.1.2 Americas Biosimilar Therapeutic Peptides Forecast
10.1.3 APAC Biosimilar Therapeutic Peptides Forecast
10.1.4 Europe Biosimilar Therapeutic Peptides Forecast
10.1.5 Middle East & Africa Biosimilar Therapeutic Peptides Forecast
10.2 Americas Biosimilar Therapeutic Peptides Forecast by Country (2024-2029)
10.2.1 United States Biosimilar Therapeutic Peptides Market Forecast
10.2.2 Canada Biosimilar Therapeutic Peptides Market Forecast
10.2.3 Mexico Biosimilar Therapeutic Peptides Market Forecast
10.2.4 Brazil Biosimilar Therapeutic Peptides Market Forecast
10.3 APAC Biosimilar Therapeutic Peptides Forecast by Region (2024-2029)
10.3.1 China Biosimilar Therapeutic Peptides Market Forecast
10.3.2 Japan Biosimilar Therapeutic Peptides Market Forecast
10.3.3 Korea Biosimilar Therapeutic Peptides Market Forecast
10.3.4 Southeast Asia Biosimilar Therapeutic Peptides Market Forecast
10.3.5 India Biosimilar Therapeutic Peptides Market Forecast
10.3.6 Australia Biosimilar Therapeutic Peptides Market Forecast
10.4 Europe Biosimilar Therapeutic Peptides Forecast by Country (2024-2029)
10.4.1 Germany Biosimilar Therapeutic Peptides Market Forecast
10.4.2 France Biosimilar Therapeutic Peptides Market Forecast
10.4.3 UK Biosimilar Therapeutic Peptides Market Forecast
10.4.4 Italy Biosimilar Therapeutic Peptides Market Forecast
10.4.5 Russia Biosimilar Therapeutic Peptides Market Forecast
10.5 Middle East & Africa Biosimilar Therapeutic Peptides Forecast by Region (2024-2029)
10.5.1 Egypt Biosimilar Therapeutic Peptides Market Forecast
10.5.2 South Africa Biosimilar Therapeutic Peptides Market Forecast
10.5.3 Israel Biosimilar Therapeutic Peptides Market Forecast
10.5.4 Turkey Biosimilar Therapeutic Peptides Market Forecast
10.5.5 GCC Countries Biosimilar Therapeutic Peptides Market Forecast
10.6 Global Biosimilar Therapeutic Peptides Forecast by Type (2024-2029)
10.7 Global Biosimilar Therapeutic Peptides Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Biosimilar Therapeutic Peptides Product Offered
11.1.3 Pfizer Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Biosimilar Therapeutic Peptides Product Offered
11.2.3 GlaxoSmithKline Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 GlaxoSmithKline Main Business Overview
11.2.5 GlaxoSmithKline Latest Developments
11.3 li Lilly and Company
11.3.1 li Lilly and Company Company Information
11.3.2 li Lilly and Company Biosimilar Therapeutic Peptides Product Offered
11.3.3 li Lilly and Company Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 li Lilly and Company Main Business Overview
11.3.5 li Lilly and Company Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Biosimilar Therapeutic Peptides Product Offered
11.4.3 Sanofi Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Takeda Pharmaceuticals
11.5.1 Takeda Pharmaceuticals Company Information
11.5.2 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Product Offered
11.5.3 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Takeda Pharmaceuticals Main Business Overview
11.5.5 Takeda Pharmaceuticals Latest Developments
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Information
11.6.2 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Product Offered
11.6.3 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Teva Pharmaceuticals Main Business Overview
11.6.5 Teva Pharmaceuticals Latest Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Biosimilar Therapeutic Peptides Product Offered
11.7.3 Amgen Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Amgen Main Business Overview
11.7.5 Amgen Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Biosimilar Therapeutic Peptides Product Offered
11.8.3 AstraZeneca Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Novartis AG
11.9.1 Novartis AG Company Information
11.9.2 Novartis AG Biosimilar Therapeutic Peptides Product Offered
11.9.3 Novartis AG Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Novartis AG Main Business Overview
11.9.5 Novartis AG Latest Developments
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Information
11.10.2 Novo Nordisk Biosimilar Therapeutic Peptides Product Offered
11.10.3 Novo Nordisk Biosimilar Therapeutic Peptides Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Novo Nordisk Main Business Overview
11.10.5 Novo Nordisk Latest Developments
12 Research Findings and Conclusion
*If Applicable.